Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.

International Journal of Rheumatic Diseases
Senthuran ShivakumarArduino A Mangoni

Abstract

There is limited information regarding the effectiveness of endothelin receptor antagonists (ERA) in patients with connective tissue disease-pulmonary arterial hypertension (CTD-PAH), a condition that is characterized by poorer clinical outcomes compared to other PAH subtypes. To conduct a systematic review and meta-analysis of the effectiveness and safety of ERA in CTD-PAH. A literature search, using MEDLINE, COCHRANE, CINAHL and EMBASE databases was conducted, from inception to May 2019 to identify randomized control studies of ERA, as monotherapy or in combination with phosphodiesterase type 5 inhibitors (PDE5i), in CTD-PAH. A protocol was registered in PROSPERO (CRD42019136956). Efficacy outcomes, including the 6-minute walk distance (6MWD) and composite clinical failure endpoints (CFE), and safety outcomes were evaluated. A total of 13 studies, including 784 CTD-PAH participants, were identified. ERA, as monotherapy, did not reduce the risk of CFE compared to placebo (odds ratio [OR] 0.77, 95% CI 0.50-1.19, P = .25). By contrast, combination therapy (ERA + PDE5i) significantly reduced the risk of developing CFE vs monotherapy (OR 0.54, 95% CI 0.32-0.90, P = .02). 6MWD did not improve when comparing monotherapy vs placebo (...Continue Reading

References

Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Jan 23, 2004·Cardiovascular Research·Nazzareno GaliéAngelo Branzi
Jun 19, 2007·BMC Medical Informatics and Decision Making·Connie SchardtPaul Fontelo
Jul 2, 2008·The European Respiratory Journal·M R WilkinsH A Ghofrani
Oct 22, 2008·American Journal of Respiratory and Critical Care Medicine·Robin CondliffeJ Gerry Coghlan
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Jan 25, 2011·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Robyn J BarstUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Oct 15, 2011·Annals of the Rheumatic Diseases·Philip J ClementsUNKNOWN Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators
Nov 28, 2012·Annals of the Rheumatic Diseases·David LaunayMarc Humbert
Aug 30, 2013·The New England Journal of Medicine·Tomás PulidoUNKNOWN SERAPHIN Investigators
Nov 19, 2014·Global Cardiology Science & Practice·Adrian H Chester, Magdi H Yacoub
Dec 3, 2014·JACC. Heart Failure·Richard N ChannickNazzareno Galiè
Feb 24, 2015·F1000prime Reports·Robin Condliffe, Luke S Howard
Apr 17, 2015·Anatolian Journal of Cardiology·Rengin Demir, Mehmet Serdar Küçükoğlu
Jun 27, 2015·The European Respiratory Journal·Vallerie McLaughlinMarius M Hoeper
Aug 21, 2015·American Journal of Respiratory and Critical Care Medicine·Rennie L RheeSteven M Kawut
Aug 27, 2015·The New England Journal of Medicine·Nazzareno GalièUNKNOWN AMBITION Investigators
Sep 12, 2015·International Journal of Evidence-based Healthcare·Catalin TufanaruEdoardo Aromataris
Dec 22, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Sean Gaine, Vallerie McLaughlin
Mar 8, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Marsha BurksNazzareno Galiè
Aug 30, 2019·BMJ : British Medical Journal·Jonathan A C SterneJulian P T Higgins

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.